“In an effort to streamline our operating structure and focus on core OGM products, we are phasing out First Step and Next Step Dx clinical services products and our Fragile X test, which are legacy, non-OGM tests. In 2023, these products generated around $7.0 million of the overall $36.1 million in revenues. After taking into account the financial impact of discontinued products, Bionano expects full year 2024 revenue to be in the range of $37.0 to $41.0 million and Q1 2024 revenue is expected to be in the range of $8.25 to $8.75 million. We anticipate installation of 80 to 100 new OGM systems in 2024, with a projected 2024 installed base range of 381 to 401 OGM systems. This range reflects some anticipated Saphyr to Stratys upgrades.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNGO:
- Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
- Options Volatility and Implied Earnings Moves Today, March 05, 2024
- Options Volatility and Implied Earnings Moves This Week, March 04 – March 07, 2024
- BNGO Upcoming Earnings Report: What to Expect?
- Bionano to Present at TD Cowen’s 44th Annual Health Care Conference
